C22orf31

Across TCGA pan-cancer cohorts, C22orf31 RNA is linked to patient survival in 1 of 34 cancer types, making it a survival-associated C22orf31 data layer compared with 6 for mutation status and 1 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher C22orf31 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated C22orf31 expression acts as an unfavorable survival marker.

SCLC are the cancer types where C22orf31 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	DFS	Quartile	III,IV	0.251	0.666	.002	13	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

C22orf31–SCLC (DFS)

Open the SCLC breakdown →